PDB56 COSTS ASSOCIATED WITH INITIATING EMPAGLIFLOZIN VERSUS OTHER ANTIHYPERGLYCEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE: A RETROSPECTIVE COHORT STUDY